Girmenia Corrado, Busca Alessandro, Candoni Anna, Cesaro Simone, Luppi Mario, Nosari Anna Maria, Pagano Livio, Rossi Giuseppe, Venditti Adriano, Aversa Franco
Dipartimento di Ematologia, Oncologia, e Dermatologia, Azienda Policlinico Umberto I, Rome.
A.O.U. Città della Salute e della Scienza, Dipartimento di Oncologia, SSD Trapianto allogenico di cellule staminali, Turin, Italy.
Med Mycol. 2019 Apr 1;57(Supplement_2):S127-S137. doi: 10.1093/mmy/myy091.
In the attempt to establish definitions and provide shared approaches to breakthrough invasive fungal diseases (br-IFD) in acute myeloid leukemia (AML) patients submitted to intensive chemotherapy and receiving triazoles as mould active primary antifungal prophylaxis (MA-PAP), literature on br-IFD in AML patients receiving triazoles MA-PAP was reviewed and a Consensus Development Conference Project was convened. The following four candidate key-questions were generated and formed the set of questions of the present document: "definition of br-IFD," "diagnostic strategy during MA-PAP to detect br-IFD," "possible causes of MA-PAP failure," "management of br-IFD."
为了给接受强化化疗并接受三唑类药物作为霉菌活性一级抗真菌预防（MA-PAP）的急性髓系白血病（AML）患者的突破性侵袭性真菌病（br-IFD）建立定义并提供共同的方法，我们回顾了接受三唑类MA-PAP的AML患者中br-IFD的相关文献，并召开了一次共识发展会议项目。由此产生了以下四个候选关键问题，并构成了本文件的问题集：“br-IFD的定义”、“MA-PAP期间检测br-IFD的诊断策略”、“MA-PAP失败的可能原因”、“br-IFD的管理”。
